Iron, as an essential micronutrient, plays a crucial role in host-pathogen interactions. In order to limit the growth of the pathogen, a common strategy of innate immunity includes withdrawing available iron to interfere with the cellular processes of the microorganism. Against that, unicellular parasites have developed powerful strategies to scavenge iron, despite the effort of the host. Iron-sequestering compounds, such as the approved and potent chelator deferoxamine (DFO), are considered a viable option for therapeutic intervention. Since iron is heavily utilized in the mitochondrion, targeting iron chelators in this organelle could constitute an effective therapeutic strategy. This work presents mitochondrially targeted DFO, mitoDFO, as a candidate against a range of unicellular parasites with promising in vitro efficiency. Intracellular Leishmania infection can be cleared by this compound, and experimentation with Trypanosoma brucei 427 elucidates its possible mode of action. The compound not only affects iron homeostasis but also alters the physiochemical properties of the inner mitochondrial membrane, resulting in a loss of function. Furthermore, investigating the virulence factors of pathogenic yeasts confirms that mitoDFO is a viable candidate for therapeutic intervention against a wide spectrum of microbe-associated diseases.

Centre for Infectious Diseases Parasitology Heidelberg University Hospital Heidelberg 69120 Germany

Department of Organic Chemistry Faculty of Science Charles University Prague 128 00 Czech Republic

Department of Parasitology Faculty of Science Charles University BIOCEV Vestec 25250 Czech Republic

Graduate Program in Areas of Basic and Applied Biology Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto Porto 4050 313 Portugal

Institute of Biotechnology Czech Academy of Sciences BIOCEV Vestec 25250 Czech Republic

Institute of Parasitology Biology Centre Academy of Sciences of the Czech Republic Branišovská 1160 31 České Budějovice 37005 Czech Republic

Laboratory of Clinical Pathophysiology Diabetes Centre Institute for Clinical and Experimental Medicine Videnska 1958 9 140 21 Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24007171

003      

CZ-PrNML

005      

20240423155752.0

007      

ta

008      

240412s2024 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/acsinfecdis.3c00529 $2 doi

035    __

$a (PubMed)38287902

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Arbon, Dominik $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic $1 https://orcid.org/0000000224595446

245    10

$a Chelation of Mitochondrial Iron as an Antiparasitic Strategy / $c D. Arbon, J. Mach, A. Čadková, A. Sipkova, J. Stursa, K. Klanicová, M. Machado, M. Ganter, V. Levytska, D. Sojka, J. Truksa, L. Werner, R. Sutak

520    9_

$a Iron, as an essential micronutrient, plays a crucial role in host-pathogen interactions. In order to limit the growth of the pathogen, a common strategy of innate immunity includes withdrawing available iron to interfere with the cellular processes of the microorganism. Against that, unicellular parasites have developed powerful strategies to scavenge iron, despite the effort of the host. Iron-sequestering compounds, such as the approved and potent chelator deferoxamine (DFO), are considered a viable option for therapeutic intervention. Since iron is heavily utilized in the mitochondrion, targeting iron chelators in this organelle could constitute an effective therapeutic strategy. This work presents mitochondrially targeted DFO, mitoDFO, as a candidate against a range of unicellular parasites with promising in vitro efficiency. Intracellular Leishmania infection can be cleared by this compound, and experimentation with Trypanosoma brucei 427 elucidates its possible mode of action. The compound not only affects iron homeostasis but also alters the physiochemical properties of the inner mitochondrial membrane, resulting in a loss of function. Furthermore, investigating the virulence factors of pathogenic yeasts confirms that mitoDFO is a viable candidate for therapeutic intervention against a wide spectrum of microbe-associated diseases.

650    12

$a železo $7 D007501

650    _2

$a deferoxamin $x chemie $7 D003676

650    _2

$a antiparazitární látky $x farmakologie $7 D000977

650    _2

$a chelátory železa $x farmakologie $x terapeutické užití $7 D007502

650    _2

$a mitochondrie $7 D008928

650    12

$a antiinfekční látky $7 D000890

655    _2

$a časopisecké články $7 D016428

700    1_

$a Mach, Jan $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic

700    1_

$a Čadková, Aneta $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic

700    1_

$a Sipkova, Anna $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic

700    1_

$a Stursa, Jan $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic

700    1_

$a Klanicová, Kristýna $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Department of Organic Chemistry, Faculty of Science, Charles University, Prague 128 00, Czech Republic

700    1_

$a Machado, Marta $u Graduate Program in Areas of Basic and Applied Biology, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto 4050-313, Portugal $u Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany

700    1_

$a Ganter, Markus $u Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany

700    1_

$a Levytska, Viktoriya $u Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic

700    1_

$a Sojka, Daniel $u Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic

700    1_

$a Truksa, Jaroslav $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic

700    1_

$a Werner, Lukáš $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic

700    1_

$a Sutak, Robert $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic $1 https://orcid.org/0000000155881683 $7 xx0254258

773    0_

$w MED00205751 $t ACS infectious diseases $x 2373-8227 $g Roč. 10, č. 2 (2024), s. 676-687

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38287902 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423155749 $b ABA008

999    __

$a ok $b bmc $g 2081264 $s 1216938

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 10 $c 2 $d 676-687 $e 20240130 $i 2373-8227 $m ACS infectious diseases $n ACS Infect Dis $x MED00205751

GRA    __

$a U10 CA021115 $p NCI NIH HHS $2 United States

LZP    __

$a Pubmed-20240412